Blood and Plasma-Derived Product Approvals in India: Regulatory and Quality Expectations

Blood and Plasma-derived Medicinal products (PDMPs) — including immunoglobulins, albumin, clotting factors, and hyperimmune globulins — occupy a critical and highly regulated niche in India’s healthcare system. These products are lifesaving for patients with bleeding disorders, immune deficiencies, burns, and liver disease. India’s demand for PDMPs significantly exceeds domestic supply, making the country an important market for global plasma fractionators.

Regulatory approval for blood and plasma-derived products involves a stringent multi-layered process — encompassing CDSCO review, NIB Kasauli batch testing, state licensing, and compliance with viral safety, cold chain, and GMP standards that are among the most demanding in the regulatory landscape.

1. Regulatory Classification and Governing Framework

Blood and plasma-derived products are regulated in India under:

1. The Drugs and Cosmetics Act, 1940 — Schedule C (biological and special products requiring special storage)
2. The NDCT Rules, 2019 — for New Drug and Clinical Trial requirements
3. The National Blood Policy, 2002 and NBTC guidelines — governing blood banking and component separation

PDMPs are classified as ‘Biological Products’ requiring DCGI approval at the national level, with manufacturing and storage licences issued by State Drug Authorities. Imported PDMPs additionally require GMP compliance certificates from the exporting country’s NRA.

2. Viral Safety — The Non-Negotiable Foundation

2.1 Donor Screening

All plasma donors must be screened for HIV-1/2, HBV (HBsAg), HCV, HTLV-I/II, and syphilis using validated NAT and serology assays. Individual donor plasma NAT testing is mandatory for high-risk viruses. Traceability from donor to final product is a core expectation in the quality dossier.

2.2 Viral Inactivation and Removal Steps

The manufacturing process must include at least two orthogonal virus inactivation and removal steps. CDSCO-accepted methods include:

4. Solvent/Detergent (S/D) treatment — effective against enveloped viruses
5. Pasteurisation (60°C, 10 hours) — for albumin and some immunoglobulins
6. Nanofiltration — effective against both enveloped and non-enveloped viruses
7. Low pH incubation — additional inactivation step for IgG products

Validation studies demonstrating virus clearance capacity (log10 reduction values) for relevant model viruses (MVM, PRV, HIV, BVDV, HAV) must be included in Module 3.

2.3 Lookback and Recall Programmes

A robust lookback programme — tracing products from a donor subsequently found positive for a blood-borne pathogen — must be documented. India requires donor-to-product traceability for a minimum of 10 years.

3. NIB Kasauli: Batch Release Requirements

Every commercial batch of a plasma-derived product must be submitted to NIB Kasauli for independent testing before release into the Indian market. NIB conducts potency, purity, sterility, and safety tests per Indian Pharmacopoeia and WHO standards. Key planning considerations:

8. Batch release timelines typically range from 8 to 16 weeks — this must be factored into supply chain planning
9. NIB may request additional testing if product characteristics deviate from established specifications
10. Establishing a direct relationship with NIB Kasauli — providing reference standard preparations and validated test methods — significantly facilitates the batch release process

4. GMP Expectations

CDSCO applies WHO GMP guidelines for blood-derived products (WHO TRS 999, Annex 4) as the minimum standard for foreign manufacturers. Indian manufacturers must additionally comply with Schedule M (revised 2023). Key GMP considerations include:

11. Process validation for each viral inactivation and removal step
12. Environmental monitoring and cleanroom qualification for aseptic filling operations
13. Cold chain qualification from bulk manufacturing through fill-finish and distribution
14. Change control procedures and deviation management documentation

CDSCO may conduct on-site GMP inspections of foreign plasma fractionation facilities not already approved by WHO, EMA, or USFDA. Companies from recognised GMP jurisdictions can submit GMP certificates in lieu of CDSCO inspection, but inspection may still be requested.

5. State Licensing for Blood Banks and Storage Facilities

In addition to national CDSCO marketing approval, blood and plasma-derived products require state-level licensing for blood banks, storage facilities, and distribution establishments under Form 28-D. For importers distributing nationally, warehouse and cold chain storage facilities in each state of operation may require separate state licensing — adding regulatory complexity to distribution strategy planning.

6. Cold Chain and Storage Obligations

Most immunoglobulins and clotting factors require storage at 2-8°C throughout the supply chain. India’s climate — with summer temperatures exceeding 45°C in certain states — places particular demands on cold chain infrastructure. CDSCO requires:

15. Validated cold chain transport containers and logistics from port of entry to final distribution
16. Continuous temperature monitoring with alarm systems at all storage facilities
17. Cold chain excursion protocols — documented procedures for handling temperature excursions
18. Distributor and pharmacy cold chain qualification audits

7. Strategic Recommendations

19. Establish NIB Kasauli relationships early — share characterisation data and validated test methods before commercial supply
20. Ensure WHO, EMA, or USFDA GMP certification is current and covers all relevant manufacturing operations
21. Build India-specific stability data under Zone IVb conditions for all temperature-sensitive products
22. Map state licensing requirements before planning distribution infrastructure
23. Partner with an established Indian distributor with existing cold chain infrastructure and state licence holdings

Conclusion

Blood and plasma-derived product approval in India is one of the most technically rigorous regulatory pathways in the country’s biological product framework. The combination of CDSCO marketing authorisation, NIB Kasauli batch release, viral safety validation, GMP compliance, and cold chain requirements create a multi-layered compliance burden — one that protects India’s patients and aligns with international best practice.

CliniExperts Services provides specialised regulatory support for blood and plasma-derived product approvals in India — from dossier preparation and CDSCO interaction to NIB Kasauli coordination, GMP gap analysis, and state licensing strategy. Our team has navigated the full complexity of this regulatory landscape on behalf of global plasma fractionators and blood product manufacturers.